The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first ...

Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

First-of-its-kind Edwards SAPIEN M3 transcatheter mitral valve system secures FDA approval for transseptal mitral ...

Edwards Lifesciences (EW) announced its SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal ...

Almost 20 years’ worth of follow-up in an international registry shows that patients with degenerative mitral regurgitation who underwent mitral valve (MV) repair had better survival, fewer ...

Patients who underwent mitral valve replacement had a more than threefold higher 10-year rate of infective endocarditis than those at moderate risk for the disease, whereas undergoing mitral valve ...

Bioprosthetic valves lasts about 10-15 years. These are usually obtained from animals or human organ donors. Tissue valves seem to improve the patient’s hemodynamics, but tend to stiffen in 10-15 ...

Surgery is thought to be life-saving for people who have ischemic mitral regurgitation, but it is unknown whether surgical repair or surgical replacement of the mitral valve is the better procedure.

CONGENITAL mitral stenosis, sufficiently severe to cause recurrent heart failure and syncopal episodes in infancy, is rarely compatible with life beyond two years of age. 1 Except for 1 reported case ...